Medacta Lowers 2026 Revenue and Margin Guidance
Medacta Group SA has revised its financial outlook for the 2026 fiscal year, citing a slower-than-expected recovery in the US healthcare market.
Stocks · News reference
Chardan Capital Initiates Coverage On Corvex with Buy Rating, Announces Price Target of $18.75
Chardan Capital analyst Bill Papanastasiou initiates coverage on Corvex (NASDAQ:MOVE) with a Buy rating and announces Price Target of $18.75.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Corvex to Host Third Quarter 2026 Earnings Call on November 12, 2026
Corvex, Inc. has scheduled its third quarter 2026 financial results announcement and conference call for November 12, 2026.
Medacta Announces Full Market Launch of Mfinity Femoral System in the US
Medacta has officially launched its Mfinity Femoral System in the United States, expanding its portfolio of orthopedic solutions for hip replacement surgery.
Corvex Inks At-The-Market Sales Agreement With Chardan Capital Markets; Co. May Offer Up To $250M Common Shares
https://www.sec.gov/ix?doc=/Archives/edgar/data/1734750/000121390026109462/ea0308409-8k_corvex.htm
8-K filing — Corvex, Inc. (MOVE)
Filed: 2026-10-14 AccNo: 0001213900-26-109462 Size: 562 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Corvex Files Prospectus Registering Resale Of Up To 4,258,068 Shares Of Common Stock For Selling Stockholders
CORVEX, INC. 4,258,068 Shares of Common Stock This prospectus relates to the potential offer and resale, from time to time by the selling stockholders named in this prospectus (the "Selling Stockholders"), of up